Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silverback Therapeutics Inc
(NQ:
SBTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 8, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silverback Therapeutics Inc
< Previous
1
2
3
4
5
Next >
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
February 23, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
February 22, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023
February 09, 2023
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 08, 2022
From
Silverback Therapeutics, Inc.
Via
GlobeNewswire
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX
October 14, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silverback Therapeutics, Inc. (Nasdaq - SBTX), One Medical (Nasdaq - ONEM), Hanger, Inc. (NYSE - HNGR), VMware, Inc. (NYSE - VMW)
July 26, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX
July 22, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
SBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to Shareholders
July 21, 2022
From
Halper Sadeh LLP
Via
Business Wire
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
July 21, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
May 17, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
March 31, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
NASDAQ:SBTX Investor Notice: Investigation over Possible Securities Laws Violations by Silverback Therapeutics, Inc.
March 04, 2022
San Diego, CA -- (SBWIRE) -- 03/04/2022 -- Silverback Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
February 24, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 03, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
January 05, 2022
From
Silverback Therapeutics
Via
Business Wire
Final Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
January 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SBTX Final Deadline - Bronstein, Gewirtz & Grossman, LLC Reminds Silverback Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 4, 2022
January 04, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Silverback Deadline Alert
January 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Deadline Tomorrow Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
January 03, 2022
Los Angeles - (NewMediaWire) - January 03, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Silverback Therapeutics,...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SILVERBACK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Silverback Therapeutics, Inc. and Encourages Investors to Contact the Firm
January 02, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Deadline Tuesday Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 31, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Silverback Shareholder Notice
December 31, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Deadline Tuesday Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 30, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Silverback Shareholder Notice
December 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Tuesday Deadline Reminder: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Silverback Shareholder Alert
December 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
7-Day Deadline Reminder: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.